FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386979803> ?p ?o ?g. }

• W4386979803 endingPage "11" @default.
• W4386979803 startingPage "1" @default.
• W4386979803 abstract "Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination with anti-CD20 immunotherapy. In this phase 1b study (NCT02446236), patients (n = 25) with relapsed/refractory MCL received rituximab with escalating doses of lenalidomide (days 1-21) and ibrutinib 560 mg (days 1-28) of 28-day cycles. The MTD for lenalidomide was 20 mg; most common grade ≥3 adverse events were skin rashes (32%) and neutropenic fever (24%). The best ORR was 88%, CR rate was 83%, and median duration of response (DOR) was 36.92 months (95% CI 33.77, 51.37). Responses were seen even in refractory patients or with high-risk features (e.g. blastoid variant, TP53 mutation, Ki-67 > 30%). R2I was safe and tolerable in patients with R/R MCL." @default.
• W4386979803 created "2023-09-24" @default.
• W4386979803 creator A5000322069 @default.
• W4386979803 creator A5006114297 @default.
• W4386979803 creator A5008419917 @default.
• W4386979803 creator A5013717203 @default.
• W4386979803 creator A5022339242 @default.
• W4386979803 creator A5025036628 @default.
• W4386979803 creator A5034259166 @default.
• W4386979803 creator A5050845011 @default.
• W4386979803 creator A5063700584 @default.
• W4386979803 creator A5069315060 @default.
• W4386979803 creator A5075752482 @default.
• W4386979803 creator A5080732827 @default.
• W4386979803 creator A5083338149 @default.
• W4386979803 creator A5089882481 @default.
• W4386979803 creator A5090941234 @default.
• W4386979803 creator A5092762886 @default.
• W4386979803 date "2023-09-23" @default.
• W4386979803 modified "2023-10-14" @default.
• W4386979803 title "Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma" @default.
• W4386979803 cites W1799746163 @default.
• W4386979803 cites W1807588734 @default.
• W4386979803 cites W1978428538 @default.
• W4386979803 cites W1995920800 @default.
• W4386979803 cites W2000302977 @default.
• W4386979803 cites W2032482627 @default.
• W4386979803 cites W2082584333 @default.
• W4386979803 cites W2095669071 @default.
• W4386979803 cites W2098002594 @default.
• W4386979803 cites W2124235514 @default.
• W4386979803 cites W2133201432 @default.
• W4386979803 cites W2154066874 @default.
• W4386979803 cites W2169209759 @default.
• W4386979803 cites W2187899653 @default.
• W4386979803 cites W2326503318 @default.
• W4386979803 cites W2528264979 @default.
• W4386979803 cites W2604069560 @default.
• W4386979803 cites W2749289906 @default.
• W4386979803 cites W2787370436 @default.
• W4386979803 cites W2892160172 @default.
• W4386979803 cites W2917537905 @default.
• W4386979803 cites W2945874655 @default.
• W4386979803 cites W2962711446 @default.
• W4386979803 cites W2976280418 @default.
• W4386979803 cites W2985252139 @default.
• W4386979803 cites W3189823930 @default.
• W4386979803 cites W4205174173 @default.
• W4386979803 cites W4205380135 @default.
• W4386979803 cites W4206934925 @default.
• W4386979803 cites W4280556984 @default.
• W4386979803 doi "https://doi.org/10.1080/10428194.2023.2259528" @default.
• W4386979803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37740588" @default.
• W4386979803 hasPublicationYear "2023" @default.
• W4386979803 type Work @default.
• W4386979803 citedByCount "0" @default.
• W4386979803 crossrefType "journal-article" @default.
• W4386979803 hasAuthorship W4386979803A5000322069 @default.
• W4386979803 hasAuthorship W4386979803A5006114297 @default.
• W4386979803 hasAuthorship W4386979803A5008419917 @default.
• W4386979803 hasAuthorship W4386979803A5013717203 @default.
• W4386979803 hasAuthorship W4386979803A5022339242 @default.
• W4386979803 hasAuthorship W4386979803A5025036628 @default.
• W4386979803 hasAuthorship W4386979803A5034259166 @default.
• W4386979803 hasAuthorship W4386979803A5050845011 @default.
• W4386979803 hasAuthorship W4386979803A5063700584 @default.
• W4386979803 hasAuthorship W4386979803A5069315060 @default.
• W4386979803 hasAuthorship W4386979803A5075752482 @default.
• W4386979803 hasAuthorship W4386979803A5080732827 @default.
• W4386979803 hasAuthorship W4386979803A5083338149 @default.
• W4386979803 hasAuthorship W4386979803A5089882481 @default.
• W4386979803 hasAuthorship W4386979803A5090941234 @default.
• W4386979803 hasAuthorship W4386979803A5092762886 @default.
• W4386979803 hasBestOaLocation W43869798031 @default.
• W4386979803 hasConcept C121332964 @default.
• W4386979803 hasConcept C126322002 @default.
• W4386979803 hasConcept C142424586 @default.
• W4386979803 hasConcept C143998085 @default.
• W4386979803 hasConcept C197934379 @default.
• W4386979803 hasConcept C2776063141 @default.
• W4386979803 hasConcept C2776364478 @default.
• W4386979803 hasConcept C2776694085 @default.
• W4386979803 hasConcept C2777063308 @default.
• W4386979803 hasConcept C2777525834 @default.
• W4386979803 hasConcept C2777938653 @default.
• W4386979803 hasConcept C2778461978 @default.
• W4386979803 hasConcept C2778850193 @default.
• W4386979803 hasConcept C2779338263 @default.
• W4386979803 hasConcept C2779609412 @default.
• W4386979803 hasConcept C2779878957 @default.
• W4386979803 hasConcept C2780653079 @default.
• W4386979803 hasConcept C31760486 @default.
• W4386979803 hasConcept C71924100 @default.
• W4386979803 hasConcept C87355193 @default.
• W4386979803 hasConcept C90924648 @default.
• W4386979803 hasConceptScore W4386979803C121332964 @default.
• W4386979803 hasConceptScore W4386979803C126322002 @default.
• W4386979803 hasConceptScore W4386979803C142424586 @default.

• next